Search: WFRF:(Van Veldhuisen Dirk J.)
> (2010-2014) >
Fibrosis Marker Syn...
Fibrosis Marker Syndecan-1 and Outcome in Patients With Heart Failure With Reduced and Preserved Ejection Fraction
-
- Tromp, Jasper (author)
- University of Groningen, Netherlands
-
- van der Pol, Atze (author)
- University of Groningen, Netherlands
-
- Klip, IJsbrand T. (author)
- University of Groningen, Netherlands
-
show more...
-
- de Boer, Rudolf A. (author)
- University of Groningen, Netherlands
-
- Jaarsma, Tiny (author)
- Linköpings universitet,Hälsa, Aktivitet, Vård (HAV),Filosofiska fakulteten
-
- van Gilst, Wiek H. (author)
- University of Groningen, Netherlands
-
- Voors, Adriaan A. (author)
- University of Groningen, Netherlands
-
- van Veldhuisen, Dirk J. (author)
- University of Groningen, Netherlands
-
- van der Meer, Peter (author)
- University of Groningen, Netherlands
-
show less...
-
(creator_code:org_t)
- American Heart Association, 2014
- 2014
- English.
-
In: Circulation Heart Failure. - : American Heart Association. - 1941-3289 .- 1941-3297. ; 7:3, s. 457-U119
- Related links:
-
https://urn.kb.se/re...
-
show more...
-
https://doi.org/10.1...
-
show less...
Abstract
Subject headings
Close
- Background-Syndecan-1 is a member of the proteoglycan family involved in cell-matrix interactions. Experimental studies showed that syndecan-1 is associated with inflammation in acute myocardial infarction and remodeling. The goal of this study was to explore the role of syndecan-1 in human heart failure (HF). Methods and Results-We analyzed plasma syndecan-1 levels in 567 patients with chronic HF. Primary end point was a composite of all-cause mortality and rehospitalization for HF at 18 months. Mean age was 71.0 +/- 11.0 years, 38% was women, and mean left ventricular ejection fraction was 32.5 +/- 14.0%. Median syndecan-1 levels were 20.1 ng/mL (interquartile range, 13.9-27.7 ng/mL). Patients with higher syndecan-1 levels were more often men, had higher N-terminal probrain-type natriuretic peptide levels, and worse renal function. Multivariable regression analyses showed a positive correlation between syndecan-1 levels and markers of fibrosis and remodeling but no correlation with inflammation markers. Interaction analysis revealed an interaction between left ventricular ejection fraction and syndecan-1 (P=0.047). A doubling of syndecan-1 was associated with an increased risk of the primary outcome in patients with HF with preserved ejection fraction (hazard ratio, 2.10; 95% confidence interval, 1.14-3.86; P=0.017) but not in patients with HF with reduced ejection fraction (hazard ratio, 0.95; 95% confidence interval, 0.71-1.27; P=0.729). Finally, syndecan-1 enhanced risk classification in patients with HF with preserved ejection fraction when added to a prediction model with established risk factors. Conclusions-In patients with HF, syndecan-1 levels correlate with fibrosis biomarkers pointing toward a role in cardiac remodeling. Syndecan-1 was associated with clinical outcome in patients with HF with preserved ejection fraction but not in patients with HF with reduced ejection fraction.
Keyword
- fibrosis; heart failure; prognosis; syndecan-1
- SOCIAL SCIENCES
- SAMHÄLLSVETENSKAP
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
To the university's database